Welcome! Login | Register
 

Guest MINDSETTERâ„¢ Warren Tolman: Candidate for Attorney General—This race for Attorney General is about leadership.…

Smart Benefits: Two Regs Issued on Contraceptive Coverage—Two regulations on contraceptive coverage were recently issued…

Junior League of Worcester Kicked Off 90th Year With a Move—The Junior League of Worcester (JLW) and its…

Fall Activities for the Whole Family—Mark your calendars for the best activities of…

Worcester Pride to Host First Annual Youth Dance—Worcester Pride will host its first annual youth…

Friday Financial Five - August 29, 2014—The Tax Foundation has put together a helpful…

The Cellar: Late Summer Values—While this week saw some fantastic weather there…

See Flamenco Dancing with Edmy Ortiz at the Worcester PopUp with Your Woo Card—The weekend is fast approaching, and GoLocalWorcester brings…

Newport Manners & Etiquette: Mending Breaches—Do you have to give a wedding present…

Arrivals & Departures Highlight Emotional Day At Gillette Stadium—The New England Patriots and New England Revolution…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.

 

You Must be Logged In to Comment